Tumor-derived extracellular vesicles (EVs) are emerging as an important mode of intercellular communication, capable of transferring biologically active molecules that facilitate the malignant growth and metastatic process. CD133 (Prominin-1), a stem cell marker implicated in tumor initiation, differentiation and resistance to anti-cancer therapy, is reportedly associated with EVs in various types of cancer. However, little is known about the factors that regulate the release of these CD133+ EVs. Here, we report that the HDAC6 inhibitor tubacin promoted the extracellular release of CD133+ EVs from human FEMX-I metastatic melanoma and Caco-2 colorectal carcinoma cells, with a concomitant downregulation of intracellular CD133. This effect was specific for tubacin, as inhibition of HDAC6 deacetylase activity by another selective HDAC6 inhibitor, ACY-1215 or the pan-HDAC inhibitor trichostatin A (TSA), and knockdown of HDAC6 did not enhance the release of CD133+ EVs. The tubacin-induced EV release was associated with changes in cellular lipid composition, loss of clonogenic capacity and decrease in the ability to form multicellular aggregates. These findings indicate a novel potential anti-tumor mechanism for tubacin in CD133-expressing malignancies.

Chao, O.S., Chang, T.C., Di Bella, M.A., Alessandro, R., Anzanello, F., Rappa, G., et al. (2017). The HDAC6 Inhibitor tubacin induces release of CD133+ extracellular vesicles from cancer cells. JOURNAL OF CELLULAR BIOCHEMISTRY, 118(12), 4414-4424 [10.1002/jcb.26095].

The HDAC6 Inhibitor tubacin induces release of CD133+ extracellular vesicles from cancer cells

DI BELLA, Maria Antonietta;ALESSANDRO, Riccardo;
2017-01-01

Abstract

Tumor-derived extracellular vesicles (EVs) are emerging as an important mode of intercellular communication, capable of transferring biologically active molecules that facilitate the malignant growth and metastatic process. CD133 (Prominin-1), a stem cell marker implicated in tumor initiation, differentiation and resistance to anti-cancer therapy, is reportedly associated with EVs in various types of cancer. However, little is known about the factors that regulate the release of these CD133+ EVs. Here, we report that the HDAC6 inhibitor tubacin promoted the extracellular release of CD133+ EVs from human FEMX-I metastatic melanoma and Caco-2 colorectal carcinoma cells, with a concomitant downregulation of intracellular CD133. This effect was specific for tubacin, as inhibition of HDAC6 deacetylase activity by another selective HDAC6 inhibitor, ACY-1215 or the pan-HDAC inhibitor trichostatin A (TSA), and knockdown of HDAC6 did not enhance the release of CD133+ EVs. The tubacin-induced EV release was associated with changes in cellular lipid composition, loss of clonogenic capacity and decrease in the ability to form multicellular aggregates. These findings indicate a novel potential anti-tumor mechanism for tubacin in CD133-expressing malignancies.
2017
Chao, O.S., Chang, T.C., Di Bella, M.A., Alessandro, R., Anzanello, F., Rappa, G., et al. (2017). The HDAC6 Inhibitor tubacin induces release of CD133+ extracellular vesicles from cancer cells. JOURNAL OF CELLULAR BIOCHEMISTRY, 118(12), 4414-4424 [10.1002/jcb.26095].
File in questo prodotto:
File Dimensione Formato  
Chao_et_al-2017-Journal_of_Cellular_Biochemistry.pdf

Solo gestori archvio

Descrizione: pdf
Tipologia: Versione Editoriale
Dimensione 1.14 MB
Formato Adobe PDF
1.14 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/248859
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 24
social impact